PRODUCT INFORMATION

Lazabemide

Item No. 11640

CAS Registry No.:	103878-84-8
Formal Name:	N-(2-aminoethyl)-5-chloro-2-pyridinecarboxamide
Synonym:	Ro 19-6327/000
MF:	$C_8H_{10}ClN_3O$
FW:	199.6
Purity:	≥95%
UV/Vis.:	λ_{max}: 230, 274 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Lazabemide is supplied as a crystalline solid. A stock solution may be made by dissolving the lazabemide in the solvent of choice, which should be purged with an inert gas. Lazabemide is soluble in the organic solvent methanol at a concentration of approximately 2 mg/ml.

Lazabemide is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, lazabemide should first be dissolved in methanol and then diluted with the aqueous buffer of choice. Lazabemide has a solubility of approximately 0.1 mg/ml in a 1:10 solution of methanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Lazabemide is an inhibitor of monoamine oxidase B (MAO-B; K_i = 0.084 µM).[1] It is selective for MAO-B over MAO-A (IC_{50}s = 0.02 and 640 µM, respectively).[2] Lazabemide inhibits rat liver MAO-B *ex vivo* with an ED_{50} value of 53 nmol/kg.[3] It inhibits ischemia-reperfusion injury-induced hydroxyl radical formation in mouse cerebral ventricles when administered at a dose of 3 mg/kg.[4]

References

1. Cesura, A.M., Gottowik, J., Lahm, H.W., *et al.* Investigation on the structure of the active site of monoamine oxidase-B by affinity labeling with the selective inhibitor lazabemide and by site-directed mutagenesis. *Eur. J. Biochem.* **236(3)**, 996-1002 (1996).
2. Ozaita, A., Olmos, G., Boronat, M.A., *et al.* Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I_2-imidazoline receptors in rat liver. *Br. J. Pharmacol.* **121(5)**, 901-912 (1997).
3. Henriot, S., Kuhn, C., Kettler, C., *et al.* Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: Preclinical and clinical findings. *J. Neural Transm. Suppl.* **41**, 321-325 (1994).
4. Suzuki, T., Akaike, N., Ueno, K., *et al.* MAO inhibitors, clorgyline and lazabemide, prevent hydroxyl radical generation caused by brain ischemia/reperfusion in mice. *Pharmacology* **50(6)**, 357-362 (1995).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM